damage to nerves
« Back to Glossary IndexNeuropathy
by Kevin Dooley, MD | Sep 1, 2017
Recent Posts
- Abcuro Raises $66 Million for New Phase 3 Ulviprubart Study in IBM
- Abcuro to Close Long-Term Extension Study of Ulviprubart in Inclusion Body Myositis
- Ulviprubart in Inclusion Body Myositis—New Results and the Question of Clinically Meaningful Slowing
- Pioglitazone in Inclusion Body Myositis: An Early but Encouraging Study
- Ulviprubart in Inclusion Body Myositis—Phase 2/3 Trial Results
Archives
- August 2026
- June 2026
- March 2026
- February 2026
- April 2024
- August 2023
- September 2022
- July 2021
- March 2021
- August 2020
- June 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- June 2019
- May 2019
- April 2019
- March 2019
- January 2019
- December 2018
- November 2018
- October 2018
- April 2018
- February 2018
- January 2018
- December 2017
- November 2017
Tags
Abcuro actvin a advocacy arimoclomol atrophy biomarker chloroquine clinical trial clinical trial endpoints clinical trials coronavirus COVAD COVID-19 diagnosis Electrical Impedance Myography falls FDA fundraising hand function helpful devices IBMFRS Inclusion Body Myositis Functional Rating Scale inflammation Living with IBM MDBR Million Dollar Bike Ride mitochondria mri muscle biopsies muscle biopsy muscle degeneration muscle strength myositis clinic myostatin patient story personal story Pioglitazone positive attitude rapamycin research specialty care sporadic inclusion body myositis ulviprubart wheelchairs Yale